Hõbekuulid vähiteraapias: teel suunatud vähiravi poole
作者： Artur Vetkas , Tõnu Rätsep , Tambet Teesalu , Kadri Toome , Hedi Hunt
关键词:
摘要: Vahiuuringute uheks keskseks eesmargiks on vahirakke normaalsetest rakkudest eristavate ravimite valjatootamine. Kliinilises kasutuses olevate vahiravimite puuduseks nende vahene selektiivsus ja sellest tingitud korvalmojud normaalsetes kudedes. Artiklis antud ulevaade suunatud valjatootamisest suundumustest. Suunatud vahiravi pohineb molekulaarsetel erinevustel vahikoe normaalsete veresoonte vahel. In vivo faagidisplei meetodi abil voimalik haigusspetsiifilisi molekulaarseid mustreid kaardistada. Selle tulemuseks peptiidid, mis seostuvad selektiivselt vahiveresoontega. Need kullerpeptiidid nagu ka teised kasvaja veresoontega seonduvad molekulid (antikehad, aptameerid) voimaldavad kasvajasse viia vahiravimeid kontrastaineid. Hiljuti avastatud kasvajakude penetreerivad peptiidid pohjustavad vahiveresoonte selektiivset lekkimist. Koos ravimitega manustatuna need ravimi valjumist veresoontest tungimist kasvajakoesse – terapeutilise indeksi paranemine.Eesti Arst 2015; 94(5):281–287
sci-hub.se 参考文章(36)
Tambet Teesalu, Kazuki N. Sugahara, Erkki Ruoslahti, Mapping of vascular ZIP codes by phage display. Methods in Enzymology. ,vol. 503, pp. 35- 56 ,(2012) , 10.1016/B978-0-12-396962-0.00002-1
Pamela A. Trail, Dalton H. King, Gene M. Dubowchik, Monoclonal antibody drug immunoconjugates for targeted treatment of cancer Cancer Immunology, Immunotherapy. ,vol. 52, pp. 328- 337 ,(2003) , 10.1007/S00262-002-0352-9
Gejing De, Jae-Kyun Ko, Tao Tan, Hua Zhu, Haichang Li, Jianjie Ma, Amphipathic tail-anchoring peptide is a promising therapeutic agent for prostate cancer treatment. Oncotarget. ,vol. 5, pp. 7734- 7747 ,(2014) , 10.18632/ONCOTARGET.2301
Trevor W. Hambley, Is anticancer drug development heading in the right direction Cancer Research. ,vol. 69, pp. 1259- 1262 ,(2009) , 10.1158/0008-5472.CAN-08-3786
Samina Nazir, Tajammul Hussain, Attiya Ayub, Umer Rashid, Alexander John MacRobert, Nanomaterials in combating cancer: therapeutic applications and developments. Nanomedicine: Nanotechnology, Biology and Medicine. ,vol. 10, pp. 19- 34 ,(2014) , 10.1016/J.NANO.2013.07.001
Erkki Ruoslahti, Targeting tumor vasculature with homing peptides from phage display. Seminars in Cancer Biology. ,vol. 10, pp. 435- 442 ,(2000) , 10.1006/SCBI.2000.0334
T. Teesalu, K. N. Sugahara, V. R. Kotamraju, E. Ruoslahti, C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration Proceedings of the National Academy of Sciences of the United States of America. ,vol. 106, pp. 16157- 16162 ,(2009) , 10.1073/PNAS.0908201106
Sara M Weis, David A Cheresh, Tumor angiogenesis: molecular pathways and therapeutic targets Nature Medicine. ,vol. 17, pp. 1359- 1370 ,(2011) , 10.1038/NM.2537
Renata Pasqualini, Erkki Ruoslahti, Organ targeting In vivo using phage display peptide libraries Nature. ,vol. 380, pp. 364- 366 ,(1996) , 10.1038/380364A0
Lilach Agemy, Kazuki N. Sugahara, Venkata Ramana Kotamraju, Kunal Gujraty, Olivier M. Girard, Yuko Kono, Robert F. Mattrey, Ji-Ho Park, Michael J. Sailor, Ana I. Jimenez, Carlos Cativiela, David Zanuy, Francisco J. Sayago, Carlos Aleman, Ruth Nussinov, Erkki Ruoslahti, Nanoparticle-induced vascular blockade in human prostate cancer Blood. ,vol. 116, pp. 2847- 2856 ,(2010) , 10.1182/BLOOD-2010-03-274258